Brind.

Eli Lilly, Camurus, and PolyPid announced a collaboration to develop long-acting incretin drugs, with PolyPid's delivery technology noted.

1 report, 1 independent Updated Jul 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Camurus Eli Lilly and Company

Keep exploring

The entities involved

Camurus
Swedish pharmaceutical company

Nothing else this week.
Eli Lilly and Company
American pharmaceutical company
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
- The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Related events

An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.Aug 1

Coverage

Newest first; wire copies grouped

Jul 15GlobeNewswireFinance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech New Report Covers PolyPid's Latest Developments; After Blockbuster Phase 3 Results in Surgical Infection P